12 June 2018 - Patients living in Alberta, Saskatchewan, Manitoba, Ontario and Newfoundland and Labrador are hopeful Uptravi will soon be accessible all across Canada.

The Pulmonary Hypertension Association of Canada (PHA Canada) and Scleroderma Canada join together in praising the Alberta, Saskatchewan, Manitoba, Ontario and Newfoundland and Labrador governments for following Quebec's lead by providing public funding for Uptravi (selexipag) for the treatment of pulmonary arterial hypertension (PAH). This action stems from the conclusion of pricing negotiations for Uptravi by the pan-Canadian Pharmaceutical Alliance (pCPA). 

The PAH and scleroderma communities are hopeful that the remaining provinces and territories across Canada will promptly follow suit to ensure that PAH specialists are able to provide optimal, individualised treatment to improve the outcomes for patients living with this potentially fatal disease.

Read Pulmonary Hypertension Association of Canada press release